Tagged: treatment RSS Toggle Comment Threads | Keyboard Shortcuts

  • admin 12:42 pm on August 3, 2014 Permalink
    Tags: 5.4 million shares, , , , , treatment,   

    VBL Therapeutics Announces Pricing Of NASDAQ IPO 

    vbltherapeuticsAugust 3, 2014 | Israeli biotech company VBL Therapeutics announced the pricing of its NASDAQ IPO. The company will sell 5,400,000 shares at $12.00 per share for a gross total of $64.8 million. In addition, VBL Therapeutics will grant underwriters 30 days to purchase up to 810,000 additional shares at the same price in order to cover over-allotments. The shares began trading on NASDAQ on July 31, 2014 under the ticker symbol VBLX with the offering due to close on August 5, 2014. VBL Therapeutics was founded in 2000 in Tel Aviv, Israel and is currently working towards developing a cure for brain cancer, which it hopes to begin Phase III clinical trials on in 2015.

     
  • admin 1:05 pm on June 9, 2014 Permalink | Reply
    Tags: cfda, , d-pharm, dp-vpa, , treatment   

    Chinese FDA Fast Tracks Approval For D-Pharm’s Epilepsy Drug 

    dpharmJune 9, 2014 | The Israeli biopharmaceutical company D-Pharm‘s anti-epileptic drug DP-VPA is set to be fast tracked for approval by the Chinese Food and Drug Administration (CFDA). The drug, which has been deemed a novel treatment by healthcare professionals, is derived from the generic drug valproic acid that is used for the treatment of epilepsy, migraine headaches and bipolar disorder. The DP-VPA treatment for epilepsy has already completed a Phase II clinical trial, and with CFDA approval, D-Pharm will develop the drug together with its local Chinese partner Jiangsu NHWA Pharmaceutical Company. D-Pharm was founded in 1993 in the Kiryat Weizmann Science Park in Rehovot and focuses on the development of innovative drugs for the treatment of central nervous system disorders.

     
    • Rochi 12:48 pm on April 18, 2016 Permalink | Reply

      You’ve impeessrd us all with that posting!

  • NoCamels Team 12:14 pm on October 27, 2013 Permalink | Reply
    Tags: , , , , secondary offering, treatment   

    ADHD Treatment Company Alcobra Raises $33M 

    ADHD Treatment Company Alcobra Raises $33MOctober 27, 2013 | Israeli company Alcobra Pharmaceuticals, which develops Attention Deficit Hyperactive Disorder (ADHD) treatments, has raised $33 million on a secondary Nasdaq offering. The company raised $25 million on its Nasdaq IPO last May.

     
  • NoCamels Team 1:39 pm on September 18, 2013 Permalink | Reply
    Tags: , , , , treatment   

    CureTech Raises $3.8M 

    CureTech Raises $3.8MSeptember 18, 2013 | Israeli biotech startup CureTech, which develops innovative ways to treat cancer, has raised $3.8 million. The finances were raised in a rights issue to majority shareholder Clal.

     
  • NoCamels Team 5:32 pm on September 10, 2013 Permalink | Reply
    Tags: , human trials, , , treatment   

    KAHR Medical Raises $2.35M 

    KAHR Medical Raises $2.35M Israeli company KAHR Medical, which develops treatments for cancer and inflammatory disease, specifically lymphoma, has announced that it has raised $2.35 million from its shareholders at a company value of $13.2 million.

    The company intends to use the proceeds in order to begin human trials in early 2014.

     
  • NoCamels Team 1:14 pm on September 10, 2013 Permalink | Reply
    Tags: acute myeloid leukemi, , , , orphan drug, treatment   

    BioLineRX Wins FDA Orphan Drug Status For Rare Leukemia Treatment 

    BioLineRX Wins FDA Orphan Drug Status For Rare Leukemia TreatmentIsraeli phramaceutcial company BioLineRX has won FDA approval for its BL-8040 acute myeloid leukemia treatment. The drug was given orphan drug status, which is given to treatments for conditions suffered by less than 200 thousand people in the US.

    Following the approval, BioLineRX will have seven years to market the drug exclusively in the US.

     
  • NoCamels Team 6:22 pm on August 13, 2013 Permalink | Reply
    Tags: amblyz, , glasses, lazy eye, orthocare, treatment   

    Opthocare Raises $1.75M To Develop Amblyz Lazy Eye Treatment Glasses 

    Opthocare Raises $1.75M To Develop Amblyz Lazy Eye Treatment GlassesIsraeli startup Opthocare, which developed Lazy-Eye treatment glasses Amblys, has raised $1.75 million. Calcalist reports that the investment was made by prominent Israeli serial inventor and medical device innovator Yossi Gross and Israeli couple Shmuel and Ronit Levinger, who own a chain of optometry stores.

     
  • NoCamels Team 1:44 pm on May 30, 2013 Permalink | Reply
    Tags: , , , , , , , treatment   

    Brainsway’s Deep TMS Treatment Approved By EU 

    Brainsway's Deep TMS Treatment Approved By EUIsraeli company Brainsway Ltd., which develops non-invasive treatments using transcranial magnetic stimulation (TMS), has received the EU’s CE Marketing stamp of approval for its Deep TMS system. The company will use the system for treating autism, Alzheimer’s and cigarette addiction.

    The approval was granted by MedCert, which is qualified for approving medical treatments by CE Marketing. Earlier this year, Brainsway won FDA and Health Canada approval.

     
  • NoCamels Team 12:10 pm on May 1, 2013 Permalink | Reply
    Tags: , , , , treatment   

    Brainsway Will Launch Deep TMS In The US 

    Brainsway Will Launch Deep TMS In The USIsraeli company Brainsway Ltd., which develops non-invasive treatments using transcranial magnetic stimulation (TMS), will launch its Deep TMS product in the US this month. The device, which is intended for treatment of major depression, won FDA approval earlier this year.

     
  • NoCamels Team 11:38 am on January 29, 2013 Permalink | Reply
    Tags: , , schizophrenia, treatment,   

    Pharmaceutical Company BiolineRX To Raise $15M 

    Pharmaceutical Company BiolineRX To Raise $15MIsraeli company BiolineRX, which is currently testing an innovative drug for treating schizophrenia, is planning a financing round, with a $15 million goal. “Calcalist” reports that the round is set to take place before the interim analysis of the clinical trial planned in March.

     
c
compose new post
j
next post/next comment
k
previous post/previous comment
r
reply
e
edit
o
show/hide comments
t
go to top
l
go to login
h
show/hide help
shift + esc
cancel